VTRS
Viatris Inc

3,785
Loading...
Loading...
News
all
press releases
Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris
CEOs at Church & Dwight, Eli Lilly, and Viatris are buying shares after stock pullbacks, signaling insider confidence.
Zacks·8d ago
News Placeholder
More News
News Placeholder
Insider Watch: 3 CEOs Buying the Dip
Large-cap stocks CHD, LLY, and VTRS have seen their respective CEOs make purchases over the last month. What do they see?
Zacks·8d ago
News Placeholder
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates
VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.
Zacks·1mo ago
News Placeholder
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·1mo ago
News Placeholder
Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates
Viatris (VTRS) delivered earnings and revenue surprises of +10.71% and +2.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Zacks·1mo ago
News Placeholder
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
Zacks·1mo ago
News Placeholder
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.
Zacks·2mo ago
News Placeholder
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris
Zacks·3mo ago
News Placeholder
Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am
Investing.com -- Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies with Buy ratings on Teva Pharmaceutical Industries (NYSE:TEVA) and Amneal Pharmaceuticals (NASDAQ:AMRX), and a Neutral rating on Viatris, citing improving fundamentals, strong free cash flow, and undemanding valuations.
investing.com·3mo ago

Latest VTRS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.